These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32040038)

  • 1. Bundling Rapid Human Immunodeficiency Virus and Hepatitis C Virus Testing to Increase Receipt of Test Results: A Randomized Trial.
    Frimpong JA; Shiu-Yee K; Tross S; D'Aunno T; Perlman DC; Strauss SM; Schackman BR; Feaster DJ; Metsch LR
    Med Care; 2020 May; 58(5):445-452. PubMed ID: 32040038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: study protocol for a hybrid design randomized controlled trial.
    Frimpong JA; D'Aunno T; Perlman DC; Strauss SM; Mallow A; Hernandez D; Schackman BR; Feaster DJ; Metsch LR
    Trials; 2016 Mar; 17(1):117. PubMed ID: 26936623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief intervention to increase emergency department uptake of combined rapid human immunodeficiency virus and hepatitis C screening among a drug misusing population.
    Merchant RC; Baird JR; Liu T; Taylor LE; Montague BT; Nirenberg TD
    Acad Emerg Med; 2014 Jul; 21(7):752-67. PubMed ID: 25125271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bundled HIV and Hepatitis C Testing in the Emergency Department: A Randomized Controlled Trial.
    Cowan E; Herman HS; Rahman S; Zahn J; Leider J; Calderon Y
    West J Emerg Med; 2018 Nov; 19(6):1049-1056. PubMed ID: 30429941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid Versus Laboratory-Based Testing for HIV and Hepatitis C at a Drug Detoxification Treatment Center: A Randomized Trial.
    Assoumou SA; Paniagua SM; Linas BP; Wang J; Samet JH; Hall J; White LF; Beckwith CG
    J Infect Dis; 2020 Sep; 222(Suppl 5):S376-S383. PubMed ID: 32877557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients.
    Hernández D; Feaster DJ; Gooden L; Douaihy A; Mandler R; Erickson SJ; Kyle T; Haynes L; Schwartz R; Das M; Metsch L
    AIDS Behav; 2016 Jan; 20(1):204-14. PubMed ID: 25952768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study protocol for Project I-Test: a cluster randomized controlled trial of a practice coaching intervention to increase HIV testing in substance use treatment programs.
    Frimpong JA; Parish CL; Feaster DJ; Gooden LK; Nelson MC; Matheson T; Siegel K; Haynes L; Linas BP; Assoumou SA; Tross S; Kyle T; Liguori TK; Toussaint O; Annane D; Metsch LR
    Trials; 2023 Sep; 24(1):609. PubMed ID: 37749635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites.
    Smith BD; Teshale E; Jewett A; Weinbaum CM; Neaigus A; Hagan H; Jenness SM; Melville SK; Burt R; Thiede H; Al-Tayyib A; Pannala PR; Miles IW; Oster AM; Smith A; Finlayson T; Bowles KE; Dinenno EA
    Clin Infect Dis; 2011 Oct; 53(8):780-6. PubMed ID: 21921221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral Hepatitis and Human Immunodeficiency Virus Testing and Linkage to Care for Individuals Enrolled in an Opioid Treatment Program.
    Rowan SE; Kamis KF; Beum R; Bryan K; Gawenus L; Colon Sanchez D; Hurley H
    J Infect Dis; 2020 Sep; 222(Suppl 5):S384-S391. PubMed ID: 32877565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of routine opt-out HIV/HCV screening on testing uptake at a syringe services program: An interrupted time series analysis.
    Bartholomew TS; Tookes HE; Serota DP; Behrends CN; Forrest DW; Feaster DJ
    Int J Drug Policy; 2020 Oct; 84():102875. PubMed ID: 32731112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.
    Schackman BR; Leff JA; Barter DM; DiLorenzo MA; Feaster DJ; Metsch LR; Freedberg KA; Linas BP
    Addiction; 2015 Jan; 110(1):129-43. PubMed ID: 25291977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends and factors in human immunodeficiency virus and/or hepatitis C virus testing and infection among injection drug users newly entering methadone maintenance treatment in Guangdong Province, China 2006-2013: a consecutive cross sectional study.
    Liu Y; Liu Y; Zou X; Chen W; Ling L
    BMJ Open; 2017 Jul; 7(7):e015524. PubMed ID: 28710214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated hepatitis C virus treatment: addressing comorbid substance use disorders and HIV infection.
    Huckans MS; Blackwell AD; Harms TA; Indest DW; Hauser P
    AIDS; 2005 Oct; 19 Suppl 3():S106-15. PubMed ID: 16251805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV and hepatitis C virus testing delays at methadone clinics in Guangdong Province, China.
    Xia YH; McLaughlin MM; Chen W; Ling L; Tucker JD
    PLoS One; 2013; 8(6):e66787. PubMed ID: 23818964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
    Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
    Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription opiate analgesics, heroin, HIV and HCV among persons who inject drugs in New York City, 2016-2018.
    Des Jarlais DC; Arasteh K; McKnight C; Feelemyer J; Perlman DC; Tross S
    Drug Alcohol Depend; 2019 Nov; 204():107459. PubMed ID: 31521951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining rapid diagnostic tests and dried blood spot assays for point-of-care testing of human immunodeficiency virus, hepatitis B and hepatitis C infections in Burkina Faso, West Africa.
    Kania D; Bekalé AM; Nagot N; Mondain AM; Ottomani L; Meda N; Traoré M; Ouédraogo JB; Ducos J; Van de Perre P; Tuaillon E
    Clin Microbiol Infect; 2013 Dec; 19(12):E533-41. PubMed ID: 23902574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respondent-driven sampling for identification of HIV- and HCV-infected people who inject drugs and men who have sex with men in India: A cross-sectional, community-based analysis.
    Solomon SS; McFall AM; Lucas GM; Srikrishnan AK; Kumar MS; Anand S; Quinn TC; Celentano DD; Mehta SH
    PLoS Med; 2017 Nov; 14(11):e1002460. PubMed ID: 29182638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of an mHealth Intervention on Hepatitis C Testing Uptake Among People With Opioid Use Disorder: Randomized Controlled Trial.
    Hochstatter KR; Gustafson DH; Landucci G; Pe-Romashko K; Cody O; Maus A; Shah DV; Westergaard RP
    JMIR Mhealth Uhealth; 2021 Feb; 9(2):e23080. PubMed ID: 33616545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computer-based alcohol reduction intervention for alcohol-using HIV/HCV co-infected Russian women in clinical care: study protocol for a randomized controlled trial.
    DiClemente RJ; Brown JL; Capasso A; Revzina N; Sales JM; Boeva E; Gutova LV; Khalezova NB; Belyakov N; Rassokhin V
    Trials; 2021 Feb; 22(1):147. PubMed ID: 33596972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.